Clinical Trial Update: A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer [Phase 1]

View source ↗

Summary

This update reports a completed Phase 1 study of MM-111 in combination with multiple treatments in patients with HER2-amplified cancers (HER2-positive cancers).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• MM-111

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: HER-2 Gene Amplification | Phase 1 | Status: COMPLETED